Navigation Links
Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Date:4/9/2012

pment Agreement.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, late-stage, oncology-focused pharmaceutical company. The company is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Syndax has worldwide rights to develop and commercialize entinostat which has shown promise in randomized clinical trials in breast and lung cancer and in phase 2 clinical trials in Hodgkin's lymphoma. Syndax is backed by top-tier venture capital firms Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. Formed in 2005, Syndax's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.   For more information please visit www.syndax.com.

Syndax Contact Information
E. Blair Schoeb 
Phone: 917.432.9275  
Email: bschoeb@syndax.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syndax Pharmaceuticals to Present at BIO Investor Forum
2. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... Gastrotomy Closure Considered Largest Hurdle in Adoption of Incisionless ... Translumenal Endoscopic Surgery (NOTES), SAN CLEMENTE, Calif., Dec. ... field of Incisionless Surgery, today announced that,its EndoSurgical Operating ... a gastrotomy (an incision in the stomach wall) during,a ...
... Protocol Assessment for Reviroc, AMSTERDAM, December 19 ... completed an End of Phase II meeting for ... Reviroc is under,development for elimination of cancer cells ... end-stage blood cancer patients. The FDA,agreed that the ...
... Inc., (Amex:,ADL), today announced that its subsidiary, Jade ... nutraceutical,diagnostic, consumer healthcare and personal care products, is ... Personal Care Center in Hangzhou,China. The state-of-the-art facility ... flagship JPGreen Health and Personal Care Center., ...
Cached Biology Technology:USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES 2Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc 2AMDL's First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China 2
(Date:12/22/2014)... , Dec. 22, 2014 Research ... has announced the addition of the ... report to their offering. ... insight provides an overview of the global ... aims to control and monitor piracy by ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... Pittsburgh of UPMC have identified a potential target ... trachomatis, the most prevalent sexually transmitted bacterial infection ... Toni Darville, MD, chief of the Division of ... strain of Chlamydia that, when investigated in an ...
... artificial heart-valve replacements face several repeat operations as they ... and must be traded for bigger ones. Researchers at ... growing valves created in the lab from a patients ... published September 11, they describe making pulmonary valves through ...
... critical to how successful treatment can be. Therefore, the ... field, where every small step is of great importance. ... Cellular Proteomics, Uppsala University researchers describe a technique that the ... bodys cells and tissues, and our knowledge of the human ...
Cached Biology News:Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 2A step toward tissue-engineered heart structures for children 2
... EZ DNA Methylation Kit uses a simplified ... DNA methylation analysis. The kit is based ... place between cytosine and sodium bisulfite where ... DNA Methylation Kits innovative in-column desulphonation reaction ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... tissue extracts (liver, kidney, spleen, and heart) and ... It was also tested with microsomal fractions prepared ... simple and reliable method for measuring NDPase activity ... the inorganic phosphate released from NDP by the ...
Biology Products: